

GSK COVID-19 Response

April 2020

GSK's Approach to responding to COVID-19



To help people do more, feel better, live longer

People

Business
Continuity

Solutions

GSK pursuing solutions based on four principles



Solutions

Using our **science, technology, portfolio** and **resources** to support development of products for **prevention** and **treatment** of COVID-19 and the overall global response

**Working in
Partnership**

**Global
approach**

**Commitment
to Access**

**Pandemic
preparedness**

GSK adjuvant-based vaccine collaborations




Collaboration approach:

- To explore potential development of adjuvanted COVID-19 vaccines
- To support development of best vaccines in fastest way possible
- GSK adjuvant technology proven in pandemic influenza H1N1:
 - **less antigen needed**
 - **more vaccine doses made**
- Data from different collaborations expected in next few months



Does not include Vir vaccine collaboration and additional collaborations not yet disclosed

Key role of adjuvanted vaccine in pandemic response



GSK and Sanofi in unprecedented collaboration to develop adjuvanted COVID-19 vaccine



- Two of the world's biggest vaccine companies
- Proven technologies
- Ability to manufacture at scale
- Long history of commitment to access


Adjuvanted COVID-19 vaccine:

- Phase I clinical trials to start in H2 2020
- If successful and subject to regulatory considerations, companies aim to make adjuvanted vaccine available by H2 2021

Committed to availability, access and investing in global long-term pandemic preparedness



Approach



We do not expect to profit from the portfolio of COVID-19 vaccines collaborations during the pandemic:

- We will responsibly price our adjuvant
- We will make our adjuvant available to the world's poorest countries, including through donations
- Any short-term profit we generate will be invested in support of coronavirus-related research & global long-term pandemic preparedness- either through GSK internal investments or with external partners
- Our approach is responsive to COVID-19 and supports a sustainable industry model

Collaboration with Vir Biotechnology to identify new solutions for coronaviruses*



- Vir Biotechnology's monoclonal antibody platform has proven success in identifying and developing antibodies as treatments for multiple pathogens
- Highly complementary to GSK's R&D focus on the science of immunology

- **First priority:** accelerate VIR-7831 and VIR-7832, two promising COVID-19 antibody candidates, into Phase II clinical trials in next 3 - 5 months
- **Longer term:** screen for novel therapeutic or preventative options for future coronavirus outbreaks

Therapeutics approach

Anti-viral medicines



Selected GSK & ViiV assets progressed to in-vitro testing against the COVID-19 virus

Prevention or treatment of secondary complications



Short-list of clinical-stage assets being reviewed for potential utility in COVID-19

Underpinned by GSK participation in global collaborative models
e.g. COVID-19 Therapeutics Accelerator, FNIH Rapid Response, Transcelerate, Pharma R&D Leaders Collaboration

Investing in global long-term pandemic preparedness



- Rapid response and scale up plans
- Regulatory support
- Research and Development
- Manufacturing capacity
- Testing and Diagnostics
- Pandemic leadership organisations

GSK global and local community support



Donations

\$10m donation
to WHO COVID-19
Solidarity Response Fund



Over £1.6m donated to support
our local communities to date

**Donation of Consumer Health
products** to 10 countries to date

**NHS Charities Together COVID
Appeal** UK employee fundraising

Diagnostic testing

A new COVID-19 diagnosis lab
In collaboration with AZ and
Cambridge University to support
UK testing



In Belgium, GSK labs will test up
to at least 6,000 samples per day

Equipment and in kind

Over 300,000 units of PPE
donated globally



New volunteering policies have
seen employees volunteer
as frontline health workers,
supporting diagnostic testing and
in non-specialist capacities